June 13th 2021
Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.
June 8th 2021
The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
June 7th 2021
Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.
June 3rd 2021
The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.
February 11th 2021
February 11, 2021 - Eganelisib, a novel PI3K-y inhibitor, demonstrated higher responses rates with nivolumab in patients with metastatic urothelial carcinoma.
February 2nd 2021
February 2, 2021 - Virtual prehabilitation could potentially improve physical activity level and exercise capacity in patients with lung cancer before they undergo surgery for their disease.
January 28th 2021
January 28, 2021- Patients with non-small cell lung cancer who experience immune-related adverse events may have better survival outcomes than those without.
January 15th 2021
January 15, 2021 - A novel artificial intelligence-based search tool made it easier for patients to find and understand cancer clinical trials, while also offering more clarity on how to enroll in them
January 14th 2021
Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.
September 21st 2020
Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.
August 1st 2020
Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.
May 31st 2020
Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.
May 29th 2020
Zanubrutinib demonstrated a higher complete response or very good partial response rate compared with ibrutinib in patients with Waldenström macroglobulinemia, although the findings were not found to be statistically significant.
May 16th 2019
A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.
February 28th 2019
Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.